2Malet-Martino M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil(capecitabine,UFT,S-1):A review[J].Oncologist,2002,7(4):288-323.
3Hoff PM.The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines,UFT/leucovorin and S-l:A review of their clinical development and therapeutic potential[J].Invest New Drugs,2000,18(4):331-342.
5Hirata K,Horikoshi N,Aiba K,et al.Pharmacokinetic study of S-1,a novel oral fluorouracil antitumor drug[J].Clin Cancer Res,1999,5(8):2000-2005.
6Sakuramoto S,Sasako M,Yamaguchi T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine[J].NEnglJMed,2007,357(18):1810-1820.
7Maehara Y.S-1 in gastric cancer:A comprehensive review[J].Gastric Cancer,2003,6(Suppl 1):2-8.
8Nagashima F,Ohtsu A,Yoshida S,et al.Japanese nationwide post-marketing survey of S-l in patients with advanced gastric cancer[J].Gastric Cancer,2005,8(1):6-11.
9Koizumi W,Narahara H,Hara T,et al.S-l plus cisplatin versus S-l alone for first-line treatment of advanced gastric cancer(SPlRITS trial):A phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.
10Ajani JA,Rodriguez W,Bodoky G,et al.Multicenter phase 3 comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS)[EB/OL].http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=63&abstractID= 10388,January 6,2010.
